VANCOUVER, BRITISH COLUMBIA--(Marketwire - April 15, 2011) - Ondine Biomedical Inc. ("Ondine" or the "Company") (TSX:OBP)(AIM:OBP) today announced that it has agreed to supply Vancouver General Hospital (VGH) with Ondine's MRSAid™ Photodisinfection System for nasal pathogen decolonization as part of a thirteen month infection control Quality Improvement Project ("QIP") being conducted at the hospital. This project, championed by Dr. Elizabeth Bryce, Regional Medical Director, Infection Control, Vancouver Coastal Health, is being undertaken with the objective of reducing the incidence of surgical site infections (SSIs) in selected surgical populations. Patients treated under this initiative will include those undergoing cardiac, spinal, orthopedic, thoracic, vascular, breast reconstruction, and neurological surgeries. The QIP, which is being sponsored by VGH & UBC Hospital Foundation funding of approximately $675,000, will focus on pre-surgical pathogen decolonization using photodisinfection of the nasal passages and full body chlorhexidine wipes for all patients treated under this initiative.
"We are excited to be collaborating on this QIP which will utilize MRSAid™, Ondine's non-antibiotic nasal pathogen decolonization system," stated Dr Bryce. "Surgical site infections are responsible for longer patient recovery times and significant costs to the health care system. In certain cases, these infections can result in patient mortality due to the presence of highly antibiotic resistant pathogens."
Dr. Cale Street of Ondine stated: "Photodisinfection provides a rapid, powerful antibacterial modality that does not generate bacterial resistance. The 10 minute, simple, painless MRSAid™ procedure is undertaken at the hospital at the time of preparation for surgery, and represents a promising approach to decolonization of acute care patients in healthcare facility settings. The MRSAid™ Photodisinfection System is designed to reduce hospital-acquired infections among high risk patients while eliminating patient compliance and antibiotic resistance concerns associated with currently used topical antibiotics."
About Ondine Biomedical Inc.
Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on developing leading edge products utilizing its patented light-activated technology, primarily for the healthcare-associated infection (HAI) market. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The Company is based in Vancouver, British Columbia, Canada, with a research and development laboratory in Bothell, Washington, USA. For additional information, please visit the Company's website at: www.ondinebio.com.
Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and other similar expressions, are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the Company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain and develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products and other risk factors identified from time to time in the Company's public filings.
The TSX Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.